Efficacy and safety of capecitabine and temozolomide regimen in advanced neuroendocrine neoplasms: a systematic review and meta-analysis
Frontiers in Endocrinology · 17.11.2026 · 17
DOI: 10.3389/fendo.2026.2013101 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Endocrinology, online erschienen am 17.11.2026. Verfasst von Matteo Tacelli und 12 weiteren Autor:innen. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Capecitabine plus temozolomide (CAPTEM) is widely used for advanced neuroendocrine neoplasms (NENs), particularly well-differentiated gastroenteropancreatic (GEP) neuroendocrine tumors, but outcome estimates and potential sources of heterogeneity remain uncertain. We aimed to update the evidence on CAPTEM efficacy and safety and explore study-level moderators of progression-free survival (PFS).
Methods
This systematic review and meta-analysis followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidance. PubMed, EMBASE, the Cochrane Library, and Google Scholar were searched from inception through April 2026 for studies of adults with advanced or metastatic NENs treated with CAPTEM. Random-effects models were used to pool median PFS (mPFS), median overall survival (mOS), and the proportion of grade 3–4 adverse events. Study quality was assessed using the Newcastle–Ottawa Scale. Prespecified subgroup analyses, leave-one-out sensitivity analysis, Egger’s test, and multivariable random-effects meta-regression were performed.
Results
Thirty-two reports comprising 2,430 CAPTEM-treated patients contributed 34 cohort rows. Pooled mPFS across 33 cohorts was 15.609 months [95% confidence interval (CI), 13.381–17.837; I ² = 99.25%], and pooled mOS across 23 cohorts was 42.833 months (95% CI, 34.792–50.874; I ² = 97.49%). Leave-one-out mPFS estimates ranged from 14.974 to 15.943 months. GEP-only cohorts had a pooled mPFS of 18.062 months, compared with 13.448 months in cohorts not restricted to GEP primaries. Across 24 analytic cohorts from 22 studies ( n = 1,208), the pooled grade 3–4 adverse-event proportion was 18% (95% CI, 14%–24%; I ² = 73.4%). No moderator was statistically significant in the updated multivariable meta-regression, and the omnibus model test was also non-significant ( p = 0.456).
Conclusions
Published CAPTEM cohorts provide descriptive survival and toxicity estimates across clinically diverse NEN populations. Extreme heterogeneity, predominantly retrospective evidence, treatment selection, and ecological analyses limit comparative and patient-level inference. Prospective controlled studies are needed to refine treatment selection and sequencing
Zitieren
APA
Tacelli, M., Marzocca, G., Lauri, G., Bina, N., Stornello, C., Massironi, S., Gallo, C., Sadowski, M. C., Partelli, S., Falconi, M., Orsi, G., Arcidiacono, P. G., & Capurso, G. (2026). Efficacy and safety of capecitabine and temozolomide regimen in advanced neuroendocrine neoplasms: a systematic review and meta-analysis. Frontiers in Endocrinology, 17. https://doi.org/10.3389/fendo.2026.2013101
Vancouver
Tacelli M, Marzocca G, Lauri G, Bina N, Stornello C, Massironi S, et al. Efficacy and safety of capecitabine and temozolomide regimen in advanced neuroendocrine neoplasms: a systematic review and meta-analysis. Frontiers in Endocrinology. 2026;17. doi:10.3389/fendo.2026.2013101
BibTeX
@article{Tacelli2026,
author = {Tacelli, Matteo and Marzocca, Giuseppe and Lauri, Gaetano and Bina, Niccolò and Stornello, Caterina and Massironi, Sara and Gallo, Camilla and Sadowski, Martin C. and Partelli, Stefano and Falconi, Massimo and Orsi, Giulia and Arcidiacono, Paolo Giorgio and Capurso, Gabriele},
title = {Efficacy and safety of capecitabine and temozolomide regimen in advanced neuroendocrine neoplasms: a systematic review and meta-analysis},
journal = {Frontiers in Endocrinology},
year = {2026},
volume = {17},
doi = {10.3389/fendo.2026.2013101}
}
EUVIMED